Phase 1 Pilocarpine effect study on Salivary Secretion & Pupillometry

  • Research type

    Research Study

  • Full title

    A Phase 1 Study to Investigate the Effect of Oral Doses of Pilocarpine on Salivary Secretion and Static Pupillometry in Healthy Subjects

  • IRAS ID

    171196

  • Contact name

    Annelize Koch

  • Contact email

    Annelize.Koch@parexel.com

  • Sponsor organisation

    Astellas

  • Eudract number

    2014-004753-13

  • Duration of Study in the UK

    0 years, 2 months, 14 days

  • Research summary

    The model tested in this study is based on the use of a medicine called pilocarpine (referred to as the “study drug”). Pilocarpine is used to treat patients with reduced salivary (spit) flow. The Sponsor is testing the study drug to see if it may be used as an experimental model in future studies, to test the effectiveness of newly developed medicines.

    The main purpose of the study is to investigate the effect of the study drug on salivary secretion. The study will also investigate the effect of the study drug on pupil (the black part in the centre of the eye) diameter. The effects (salivary secretion and pupil dilation) that the study drug has on the body is called pharmacodynamics (PD) of the study drug. The study will also try to determine how safe the study drug is and how well it is tolerated after dosing. In addition, the study will also investigate how the study drug is taken up, metabolised (chemically broken down), distributed through the body and excreted this is called the pharmacokinetics (PK) of the study drug.

    This study will recruit healthy, non-smoking, males and females between the ages of 18 and 55 years (inclusive). A total of 12 subjects will take part in the study.

    Vital signs, safety ECG measurements, safety laboratory assessments, saliva samples, adverse events and concomitant medications will be monitored throughout the entire investigational period. Blood samples for pharmacokinetic analysis will be collected.

  • REC name

    London - Brent Research Ethics Committee

  • REC reference

    15/LO/0096

  • Date of REC Opinion

    12 Mar 2015

  • REC opinion

    Further Information Favourable Opinion